Please login to the form below
Jetrea
This page shows the latest Jetrea news and features for those working in and with pharma, biotech and healthcare.
Novartis' Lucentis wins fourth NICE recommendation
The NICE recommendation is the second in the space of a week for Novartis, which two days ago received a green light for Jetrea (ocriplasmin) to treat patients with the rare
Latest news
-
NICE backs Novartis/ ThromboGenics’ eye drug
Recommends Jetrea for NHS use in England and Wales to treat the rare disease vitreomacular traction. ... NICE's recommendation limits use of Jetrea compared to its European approval, which covers all vitreomacular traction patients.
-
NICE backs Novartis' Jetrea in rare eye condition
This differs from its licence from the European Medicines Agency (EMA), which in March 2013 approved the use of Jetrea in any adult with the condition. ... Once launched, Jetrea will be marketed by Novartis' eye division Alcon, which purchased non-US
-
Alcon wins initial NICE backing for Jetrea in rare eye condition
It purchased the rights to commercialise Jetrea outside the US from its developers ThromboGenics in 2012 as part of a deal potentially worth up to 375m. ... In addition to its European licence, Jetrea won approval in October last year for the treatment
-
Novartis, ThromboGenics' eye drug Jetrea gets green light in EU
Jetrea was approved for symptomatic VMA last year in the US, where ThromboGenics has retained exclusive commercial rights, and was launched onto the market in January 2013. ... Analysts have suggested Jetrea sales could reach $500m in the US alone, with
-
Novartis' eye drug Jetrea recommended for EU approval
European regulatory authorities have backed Novartis' licence application for its new eye drug Jetrea (ocriplasmin). ... world.". Jetrea is a recombinant form of human protein (plasmin) that is administered through a one-time, single intravitreal
More from news
Approximately 4 fully matching, plus 2 partially matching documents found.
Latest appointments
-
ThromboGenics bolsters leadership team
Vangeersdaele will be leading and developing the overall commercial strategy for the company’s recently formed Jetrea business unit, which was created following ThromboGenics regaining full rights to Jetrea from Novartis. ... I am convinced that their
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn
- Landscape review reveals £1.1bn of UK funding for rare diseases
- Cancer Research UK partners with French cancer institute
- New diagnosis pathway has been launched to mark European Myeloma Day
- Impacting Lives with Rare Disease Education
- Sandoz biosimilar receives EC approval to treat MS
No results were found
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
